Research ArticleOriginal Article
Open Access

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis

Daryoush Afshari, Nasrin Moradian, Freshteh Nasiri, Nazanin Razazian, Arash Bostani and Payam Sariaslani
Neurosciences Journal October 2015, 20 (4) 357-361; DOI: https://doi.org/10.17712/nsj.2015.4.20150375

Article Figures & Data

Figures

Tables

  • Table 1

    Baseline characteristics of the patient with cerebral venous sinus thrombosis.

    CharacteristicsLMWHLMWHP-value
    n=26n=18
    n (%)
    Age1.37±10.337.66±20.90.91
    Gender (female)22 (84.6)13 (72.2)0.31
    Time to treatment, week (median)1.61±0.981.82±0.920.46
    Clinical presentation
     Headache21(80.8)17 (94.4)0.37
     Seizure12 (46.2)6 (33.3)0.39
    Loss of consciousness6 (23.1)4 (22.2)0.99
    Papilledema15 (57.7)10 (55.6)0.88
    Aphasia4 (15.4)1 (5.65)0.63
    Motor deficit10 (38.5)7 (38.9)0.97
    Sensory deficit9 (34.6)7 (38.9)0.77
    Mental disorder5 (19.2)4 (22.2)0.99
    Ocular palsy4 (15.4)3 (16.7)0.99
    Risk factor
     Fasting8 (30.8)3 (16.7)0.48
     Thrombophilia4 (15.4)2 (11.1)0.99
     Female-specific16 (61.5)12 (66.6)0.22
     Not identified7 (26.9)3 (16.7)0.48
    Number of sinus involved
     ≤220 (76.9)11 (61.1)0.25
     >26 (23.1)7 (38.9)
    CVST type
     Dural sinus25 (96.2)18 (100)0.99
     Cortical vein5 (19.2)2 (11.1)0.68
     Jugular vein0 (0.0)2 (11.1)0.16
     Deep vein6 (23.1)3 (16.7)0.71
    Brain MRI
     Infarct6 (23.1)4 (22.2)0.99
     Hemorrhage5 (19.2)4 (22.2)0.99
     No parenchyma lesions15 (57.7)10 (55.6)0.88
    Duration admission11.1±411.3±5.20.84
    Duration of heparin treatment6.8±2.17.5±2.20.36
    CVST - cerebral venous sinus thrombosis, UFH - unfractionated heparin, LMWH - low-molecular-weight heparin
  • Table 2

    Outcome of patient with cerebral venous sinus thrombosis.

    OutcomesLMWH n=26UFH n=18P-value*
    Death during hospitalization1 (3.8)1 (5.6)0.99
    NIHSS baseline3.24±43.29±4.610.74
    NIHSS discharge1.04±1.571.41±1.970.70
    NIHSS 1month0.40±0.650.53±1.070.76
    mRS baseline2.12±1.512.29±1.610.82
    mRS 1 month0.56±0.920.47±0.80.95
    P-value®0.00010.0001

    • ↵® Repeated Measurement ANOVA,

    • ↵* One-way ANOVA, NIHSS - National Institutes of Health Stroke Scale, mRS - modified rankin scale, UFH - unfractionated heparin, LMWH - low-molecular-weight heparin

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section